Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study (2019) Lamarca A, Ronot M, Moall S, Crona J, Opalinska M, Lopez C, Pezzutti D, et al. Conference contribution Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium (2019) Apostolidis L, Kreutzfeldt S, Oles M, Heining C, Hutter B, Gieldon L, Lamping M, et al. Conference contribution Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy (2019) Busse A, Spenke C, Arsenic R, Briest F, Sipos B, Kaemmerer D, Pavel ME, et al. Conference contribution Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study (2019) Pavel ME, Dromain C, Thanh TXM, Houchard A Conference contribution Acoustic Radiation Force Impulse (ARFI) Elastography in Autoimmune and Cholestatic Liver Diseases (2019) Görtz R, Gassmann L, Strobel D, Wildner D, Schellhaas B, Neurath M, Pfeifer L Journal article PU.1 controls fibroblast polarization and tissue fibrosis (2019) Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici AB, Weber S, et al. Journal article The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity (2018) Nikam A, Patankar J, Somlapura M, Lahiri P, Sachdev V, Kratky D, Denk H, et al. Journal article Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application (2018) Zundler S, Dietz L, Matzel KE, Geppert CI, Becker E, Rath T, Neurath M, Atreya R Journal article, Letter SPIONs functionalized with small peptides for binding of lipopolysaccharide, a pathophysiologically relevant microbial product. (2018) Karawacka W, Janko C, Unterweger H, Mühlberger M, Lyer S, Taccardi N, Mokhir A, et al. Journal article Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution